ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 161 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2015. The put-call ratio across all filers is 1.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $87,000 | +3.6% | 1,130 | -31.1% | 0.71% | +38.4% |
| Q1 2018 | $84,000 | +10.5% | 1,640 | 0.0% | 0.51% | +6.9% |
| Q4 2017 | $76,000 | -12.6% | 1,640 | 0.0% | 0.48% | +200.0% |
| Q3 2017 | $87,000 | -14.7% | 1,640 | 0.0% | 0.16% | -18.0% |
| Q2 2017 | $102,000 | -8.1% | 1,640 | 0.0% | 0.19% | -13.8% |
| Q1 2017 | $111,000 | +141.3% | 1,640 | +148.5% | 0.22% | +129.6% |
| Q4 2016 | $46,000 | -99.9% | 660 | 0.0% | 0.10% | +50.8% |
| Q3 2016 | $46,820,000 | +146212.5% | 660 | 0.0% | 0.06% | +150.0% |
| Q2 2016 | $32,000 | -99.9% | 660 | -34.0% | 0.03% | -35.0% |
| Q1 2016 | $63,310,000 | +56426.8% | 1,000 | 0.0% | 0.04% | -41.2% |
| Q4 2015 | $112,000 | +14.3% | 1,000 | -2.0% | 0.07% | -1.4% |
| Q3 2015 | $98,000 | – | 1,020 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |